Adriamycin PFS
Showing 1 - 25 of 1,755
Hodgkin Lymphoma Trial in Houston (Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab)
Not yet recruiting
- Hodgkin Lymphoma
- Brentuximab vedotin
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jun 20, 2023
Leukemia Trial in Portland (cyclophosphamide, cytarabine, dexamethasone)
Terminated
- Leukemia
- cyclophosphamide
- +8 more
-
Portland, OregonOHSU Knight Cancer Institute
Dec 13, 2022
Urothelial Carcinoma, Bladder Cancer Trial in Houston (Abiraterone acetate, Durvalumab, Methotrexate)
Recruiting
- Urothelial Carcinoma
- Bladder Cancer
- Abiraterone acetate
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jun 2, 2022
Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Carcinoma, SMARCB1 Negative Trial in Houston (Doxorubicin,
Recruiting
- Metastatic Kidney Medullary Carcinoma
- +4 more
- Doxorubicin
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jan 20, 2023
Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Solid Tumor Trial in New Brunswick
Active, not recruiting
- Ann Arbor Stage III Non-Hodgkin Lymphoma
- +2 more
- Cyclophosphamide
- +4 more
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Jan 28, 2023
Classical Hodgkin Lymphoma Trial in Seattle (drug, other, biological)
Recruiting
- Classical Hodgkin Lymphoma
- Dacarbazine
- +4 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 8, 2022
Metastatic Urothelial Carcinoma, Transitional Cell Carcinoma, Unresectable Transitional Cell Carcinoma Trial in Houston
Active, not recruiting
- Metastatic Urothelial Carcinoma
- +2 more
- Doxorubicin Hydrochloride
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell
Completed
- AIDS-related Diffuse Large Cell Lymphoma
- +8 more
- cyclophosphamide
- +7 more
-
Eldoret, Kenya
- +1 more
Sep 12, 2022
Localized Osteosarcoma, Metastatic Osteosarcoma, Resectable Osteosarcoma Trial (Bone Scan, Cabozantinib S-malate, Cisplatin)
Not yet recruiting
- Localized Osteosarcoma
- +3 more
- Bone Scan
- +7 more
- (no location specified)
Jan 18, 2023
Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma, Locally Advanced Leiomyosarcoma Trial in Portland (Doxorubicin
Active, not recruiting
- Advanced Soft Tissue Sarcoma
- +26 more
- Doxorubicin Hydrochloride
- +3 more
-
Portland, OregonOHSU Knight Cancer Institute
Jan 6, 2023
Breast Cancer Trial in Houston (Paclitaxel, Eribulin, 5-Fluorouracil)
Completed
- Breast Cancer
- Paclitaxel
- +5 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Aug 26, 2021
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative Trial in Bellevue, Grand Island, Omaha (drug, other,
Active, not recruiting
- Estrogen Receptor Negative
- +15 more
- Cyclophosphamide
- +6 more
-
Bellevue, Nebraska
- +3 more
Nov 30, 2022
T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma Trial in Houston (Cyclophosphamide, Cytarabine, Dexamethasone)
Recruiting
- T Acute Lymphoblastic Leukemia
- T Lymphoblastic Lymphoma
- Cyclophosphamide
- +10 more
-
Houston, TexasM D Anderson Cancer Center
Jan 11, 2023
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 Trial in
Suspended
- Anatomic Stage 0 Breast Cancer AJCC v8
- +18 more
- Celecoxib
- +6 more
-
Buffalo, New YorkRoswell Park Cancer Institute
Oct 4, 2022
Sarcoma Trial in Seattle (drug, other, biological)
Completed
- Sarcoma
- Doxorubicin Hydrochloride
- +2 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
May 3, 2021
Stage I Mantle Cell Lymphoma, Stage II Contiguous Mantle Cell Lymphoma, Stage II Non-Contiguous Mantle Cell Lymphoma Trial in
Active, not recruiting
- Stage I Mantle Cell Lymphoma
- +4 more
- Autologous Hematopoietic Stem Cell Transplantation
- +8 more
-
Buffalo, New York
- +1 more
Mar 9, 2022
Acute Adult T-Cell Leukemia/Lymphoma, Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma Trial in United
Recruiting
- Acute Adult T-Cell Leukemia/Lymphoma
- +3 more
- Cyclophosphamide
- +5 more
-
Atlanta, Georgia
- +13 more
Jan 26, 2023
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma Trial
Completed
- Anaplastic Large Cell Lymphoma, ALK-Negative
- +9 more
- Autologous Hematopoietic Stem Cell Transplantation
- +8 more
-
Duarte, California
- +7 more
Nov 4, 2022
DLBCL Trial in Houston (Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride)
Recruiting
- Diffuse Large B-Cell Lymphoma
- Acalabrutinib
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Jul 10, 2022
DLBCL Unclassifiable Trial in Houston (Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide)
Active, not recruiting
- Diffuse Large B-Cell Lymphoma Unclassifiable
- Cyclophosphamide
- +7 more
-
Houston, TexasM D Anderson Cancer Center
Feb 23, 2022
Blastoid Variant Mantle Cell Lymphoma, CD20 Positive, Mantle Cell Lymphoma Trial in Houston (drug, other, biological)
Active, not recruiting
- Blastoid Variant Mantle Cell Lymphoma
- +3 more
- Cyclophosphamide
- +10 more
-
Houston, TexasM D Anderson Cancer Center
Mar 8, 2022
Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, DLBCL
Active, not recruiting
- Adult Burkitt Lymphoma
- +4 more
- Cyclophosphamide
- +10 more
-
Chicago, Illinois
- +4 more
Feb 17, 2022
Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Mixed Cellularity
Completed
- Childhood Favorable Prognosis Hodgkin Lymphoma
- +5 more
- radiation therapy
- +11 more
-
Arcadia, CaliforniaChildren's Oncology Group
Mar 26, 2021
Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II
Active, not recruiting
- Aggressive Non-Hodgkin Lymphoma
- +13 more
- Cyclophosphamide
- +6 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Aug 18, 2022